Navigation Links
Simpler Anemia Treatment May Help Kidney Patients
Date:10/19/2007

Newer drug is given just once per month, experts say

FRIDAY, Oct. 19 (HealthDay News) -- A new approach for treating anemia in patients with severe kidney disease could help improve patients' quality of life, according to a U.S. study.

Compared with conventional therapy, giving patients an anti-anemia drug as infrequently as once a month could simplify anemia management, concluded Dr. Nathan Levin, of the Renal Research Institute in New York, and colleagues.

The findings are published in the Oct. 20 issue of The Lancet.

Conventional therapy with epoetin (a synthetic form of human erythropoietin that promotes red blood cell production) requires frequent administrations (at least once weekly), changes of dose, and close monitoring of hemoglobin concentrations.

In this study involving patients on dialysis, the researchers compared the use of a long-acting erythropoieses-stimulating agent variant of epoetin (methoxy polyethylene glycol-epoetin beta) given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times per week.

All 673 patients in the study received conventional epoetin treatment for the first four weeks of the study. After that, one group of patients received methoxy polyethylene glycol-epoetin beta every two weeks, another group received methoxy polyethylene glycol-epoetin beta every four weeks, and the third group continued receiving conventional epoetin treatment.

After about 42 weeks, there were no statistically significant differences in hemoglobin concentrations between the three groups. Based on their findings, the researchers recommended that methoxy polyethylene glycol-epoetin beta be introduced as an option for simplified management of anemia in patients on dialysis.

However, the authors of an accompanying Comment article called for more research.

"Before we can concur on a precise clinical role for this molecule, we need to explore issues other than simply the non-inferiority with other epoetins to reach certain unvalidated surrogates. Different doses and molecular characteristics of epoetins may affect patient-level endpoints, independent of achieved hemoglobin. When these issues are examined, we might be truly confident that a newer molecule is non-inferior to existing ones," wrote Dr. Rowan Walker of the Royal Melbourne Hospital and Monash University Alfred Hospital in Melbourne, Australia, and Dr. Giovanni Strippoli, of the University of Sydney, Australia, and the Mario Negri Sud Consortium in Chieti, Italy.

More information

The U.S. National Institute on Diabetes and Digestive and Kidney Diseases has more about anemia.



-- Robert Preidt



SOURCE: The Lancet, news release, Oct. 19, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Surgeons Develop Simpler Way to Cure Atrial Fibrillation
2. Detection of Malignant Breast Tumors Made Simpler and More Effective
3. Liver Regeneration may Be Simpler Than Previously Thought
4. Fight anemia by fortifying crops with iron!!!!!!!!
5. Doctors advice early anemia tests
6. Anemia Treatment for Cancer Patients
7. Anemia Treatment for Cancer Patients
8. Anemia Treatment for Cancer Patients Might Not be a Good Idea.
9. Anemia may Lead to Physical Decline
10. Gene to identify risk of stroke in sickle cell anemia
11. New treatment for babies with sickle cell anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 29, 2017 , ... The Wharton School of the University of Pennsylvania is ... made a $10 million gift to establish the Ken Moelis and Julie Taffet ... to a Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests expand ...
(Date:3/28/2017)... ... 2017 , ... Tuesday, March 28, 2017, is the annual American Diabetes Association ... Test to find out if they are at risk for developing Type 2 diabetes. ... evening sky by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, Inc., ... invited to the Siemens Healthineers annual customer education symposium, a world-class learning conference ... place from March 27 - 31, 2017 at the Atlanta Marriott Marquis in ...
(Date:3/28/2017)... ... March 28, 2017 , ... City trips ... (IBT World Travel Trends Report). As travelers visit both urban destinations, they are ... and prolonged sun exposure. In response, the outdoor industry has blurred the lines ...
(Date:3/28/2017)... ... ... Sentry Group LLC., a leader in the Personal Emergency Response System industry, introduced advanced ... These iSAFE products are the most affordable and most advanced medical alert systems on ... GPS Location and two-way calling with the push of a button on a nationwide ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TORONTO , March 28, 2017 /PRNewswire/ - ... service medical device development firm, announced today that it ... Toronto -based medical device industrial design and productization ... companies throughout North America with ... device talent spanning the design, engineering, regulatory, and manufacturing ...
(Date:3/28/2017)... and TEL AVIV, Israel , March 28, 2017 ... Israel . This new business entity, Emosis Ltd, ... dedicated to research and development of novel assays complementing the mother ... when relevant, locally support commercialization and sales development of Emosis kits. ... This strategic move ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
Breaking Medicine Technology: